

(Print or Type Responses)

1. Name and Address of Reporting Person*

(First)

(Middle)

NATIXIS PRIVATE EQUITY

5-7 RUE DE MONTTESSUY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0104				
Estimated average burden					
nours per response					

5. If Amendment, Date Original

See Footnote (3)

Filed(Month/Day/Year)

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

3. Issuer Name and Ticker or Trading Symbol

\$ (4)

4. Relationship of Reporting Person(s) to

EYEGATE PHARMACEUTICALS INC [EYEG]

2. Date of Event Requiring

02/12/2015

01/01/2015 06/06/2019

Statement (Month/Day/Year)

(Street) PARIS, IO 75007					(Check all applicable) Director Officer (give title below) Other (specify below)		Applicable Lin _X_ Form file	6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person	
(City)	(State) (Zip)		Table I - Non-Derivative Securities Beneficially Owned						
1.Title of Security (Instr. 4)				nount of Secur ficially Owned : 4)	d [. Nature of Indirec Instr. 5)	t Beneficial Ownership	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)		sable and	1		4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
		Date Exercisable	Expiration Amount or	Security	Direct (D) or Indirect (I) (Instr. 5)				
Series D Preferred	l Stock	(1)	<u>(1)</u>	Common Stock	576,564	\$ <u>(2)</u>	I	See Footnote (3)	

Common

63,442

Reporting Owners

Common Stock Warrants (right to

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
NATIXIS PRIVATE EQUITY 5-7 RUE DE MONTTESSUY PARIS, IO 75007		X			

Signatures

buy)

/s/ Authorized Signatory*	02/12/2015	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Issuer's Preferred Stock is convertible into Common Stock at any time at the holder's election. There is no expiration date for any series of Preferred Stock.
- (2) All outstanding shares of the Issuer's Series D Preferred Stock will automatically convert on a 10.96-for-one basis into Common Stock as shown in column 3 immediately upon the closing of the Issuer's initial public offering, for no additional consideration.

Represents shares and warrants held by NPE Coinvest ("NC"). Natixis Private Equity ("NPE") owns 100% of NC. NPE disclaims beneficial ownership of these securities and this report shall not be deemed an admission that NPE is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent

- (3) of its pecuniary interest therein. Voting and investment power over the shares held by NC may be deemed to be shared with NPE due to its parent relationship. Each of Dominique Sabassier ("Sabassier") and Cyrille Marcilhacy ("Marcilhacy ") are officers of NPE. Each of Sabassier and Marcilhacy disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein.
- (4) The per-share exercise price will be equal to the price per share at which shares of Common Stock are sold to the public pursuant to the Company's initial public offering.

Remarks:

*Signed under power of attorney on behalf of Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.